AVEO Pharmaceuticals, Inc Market Share, Size, Symptoms, Treatment, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'AVEO Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the AVEO Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AVEO Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

To Get Full Report Click Here @ http://www.radiantinsights.com/research/aveo-pharmaceuticals-inc-product-pipeline-review-2016

Progressive Multifocal Leukoencephalopathy Market Share, Size, Symptoms, Treatment, Analysis, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2016', provides an overview of the Progressive Multifocal Leukoencephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects.

Browse Full Report with TOC @ http://www.radiantinsights.com/research/progressive-multifocal-leukoencephalopathy-pipeline-review-h1-2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy

- The report reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Progressive Multifocal Leukoencephalopathy therapeutics and enlists all their major and minor projects

- The report assesses Progressive Multifocal Leukoencephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Progressive Multifocal Leukoencephalopathy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/progressive-multifocal-leukoencephalopathy-pipeline-review-h1-2016/request-sample

Patient Engagement Solutions Market is Expected to Reach USD 39.3 Billion by 2024: Radiant Insights

The global patient engagement solutions market is expected to reach USD 39.3 billion by 2024, according to a new report by Grand View Research, Inc. The supportive government initiatives and the rising usage and awareness of mobile healthcare services are expected to impel the market growth.

The rising prevalence of chronic conditions is the preliminary factor that is expected to advance the market growth. The mortality rate of diabetic patients was over 1.0 million in 2012, as stated by the WHO. This hike in the death rate of diabetic patients reflects the lack of knowledge about the causes, symptoms, and the preventive measures of the disease. The present patient engagement systems aid in furnishing patients with educative information; thus, empowering them to make better healthcare decisions.

Browse Full Report with TOC @ http://www.radiantinsights.com/research/patient-engagement-solutions-market

The patient engagement solutions cater to the hospitals in providing financial solutions for effective utilization of the allocated healthcare budget. Furthermore, the market players are actively volunteering in obtaining patient feedback regarding the existent solutions to develop better patient engagement plat forms with enhanced quality.

Moreover, the favorable government initiatives and the funding efforts undertaken to promote the incorporation of patient engagement solutions in the healthcare sector help in boosting the market growth. For instance, in the U.S., under the Health Information Technology for Economic and Clinical Health (HITECH) act, the government spends around USD 20 billion annually on hospitals for the installation of Electronic Health Records (EHRs), which is expected to help in improving the workflow and the quality of treatment delivery.

Further key findings from the study suggest:

The web-based delivery segment is expected to be the largest delivery mode growing at a lucrative CAGR over the forecast period.

North America is expected to dominate over the forecast period with a revenue share of over 40.0% in 2024. Favourable government initiatives, such as the Affordable Care Act (ACA) initiated by President Obama and the Health Information Technology for Economic and Clinical Health (HITECH) act, are anticipated to drive the market growth.

Asia Pacific is anticipated to emerge as the fastest growing region with a CAGR of over 20.0% over the forecast period. The increasing investments in the healthcare sector, rising awareness with regard to the varying types of patient engagement portals, and the escalating geriatric population base are estimated to catapult the demand.

Some key players of the market include Allscripts Healthcare Solutions, Inc., Cerner Corporation, Phytel, Inc., Athenahealth, Inc., McKesson Corporation, and MEDecision, Inc.

In order to curtail the competition, the key industry players are actively involved in the development of new solutions that facilitate the workflow of the existing platforms. For instance, Allscripts Healthcare Solutions, Inc. provides revenue cycle management solutions, which help in maintaining the financial health of the medical systems.

Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/patient-engagement-solutions-market/request-sample

Dermatomycoses Market Share, Size, Symptoms, Treatment, Causes, Analysis, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Dermatomycoses - Pipeline Review, H1 2016', provides an overview of the Dermatomycoses pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dermatomycoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomycoses and features dormant and discontinued projects.

Click Here For Complete Report @ http://www.radiantinsights.com/research/dermatomycoses-pipeline-review-h1-2016

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/dermatomycoses-pipeline-review-h1-2016/request-sample

Global and Chinese Dissolved Oxygen Monitor Market Size, Cost and Price, Analysis and Opportunities Forecasts 2016

The 'Global and Chinese Dissolved Oxygen Monitor Industry, 2011-2021 Market Research Report' is a professional and in-depth study on the current state of the global Dissolved Oxygen Monitor industry with a focus on the Chinese market. The report provides key statistics on the market status of the Dissolved Oxygen Monitor manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2011-2016 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Dissolved Oxygen Monitor industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2016-2021 market development trends of Dissolved Oxygen Monitor industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Dissolved Oxygen Monitor Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2011-2021 global and Chinese Dissolved Oxygen Monitor industry covering all important parameters.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/global-and-chinese-dissolved-oxygen-monitor-industry-2016

Table of Contents

Chapter One Introduction of Dissolved Oxygen Monitor Industry

1.1 Brief Introduction of Dissolved Oxygen Monitor

1.2 Development of Dissolved Oxygen Monitor Industry

1.3 Status of Dissolved Oxygen Monitor Industry

Chapter Two Manufacturing Technology of Dissolved Oxygen Monitor

2.1 Development of Dissolved Oxygen Monitor Manufacturing Technology

2.2 Analysis of Dissolved Oxygen Monitor Manufacturing Technology

2.3 Trends of Dissolved Oxygen Monitor Manufacturing Technology

Chapter Three Analysis of Global Key Manufacturers

3.1 Company A

3.1.1 Company Profile

3.1.2 Product Information

3.1.3 2011-2016 Production Information

3.1.4 Contact Information

3.2 Company B

3.2.1 Company Profile

3.2.2 Product Information

3.2.3 2011-2016 Production Information

3.2.4 Contact Information

3.3 Company C

3.2.1 Company Profile

3.3.2 Product Information

3.3.3 2011-2016 Production Information

3.3.4 Contact Information

3.4 Company D

3.4.1 Company Profile

3.4.2 Product Information

3.4.3 2011-2016 Production Information

3.4.4 Contact Information

3.5 Company E

3.5.1 Company Profile

3.5.2 Product Information

3.5.3 2011-2016 Production Information

3.5.4 Contact Information

3.6 Company F

3.6.1 Company Profile

3.6.2 Product Information

3.5.3 2011-2016 Production Information

3.6.4 Contact Information

3.7 Company G

3.7.1 Company Profile

3.7.2 Product Information

3.7.3 2011-2016 Production Information

3.7.4 Contact Information

3.8 Company H

3.8.1 Company Profile

3.8.2 Product Information

3.8.3 2011-2016 Production Information

3.8.4 Contact Information

......

......

Request Sample Copy of This Report @ http://www.radiantinsights.com/research/global-and-chinese-dissolved-oxygen-monitor-industry-2016/request-sample           

About Us:

Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

28 2nd Street,

Suite 3036 San Francisco,

CA 94105 United States

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Website: http://www.radiantinsights.com/

Email: sales@radiantinsights.com

Visit our Blog: http://chemicalsandmaterialsri.blogspot.com

Behcet Disease Market Share, Size, Symptoms, Treatment, Causes, Analysis, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Behcet Disease - Pipeline Review, H1 2016', provides an overview of the Behcet Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Behcet Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/behcet-disease-pipeline-review-h1-2016        

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Request Sample Copy of This Report @ http://www.radiantinsights.com/research/aplastic-anemia-pipeline-review-h1-2016/request-sample          

About Us:

Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

28 2nd Street,

Suite 3036 San Francisco,

CA 94105 United States

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Website: http://www.radiantinsights.com/

Email: sales@radiantinsights.com

Visit our Blog: http://chemicalsandmaterialsri.blogspot.com

Aplastic Anemia Market Share, Size, Symptoms, Treatment, Causes, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Aplastic Anemia - Pipeline Review, H1 2016', provides an overview of the Aplastic Anemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Aplastic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued projects.

Read Complete Report with TOC @ http://www.radiantinsights.com/research/aplastic-anemia-pipeline-review-h1-2016       

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Aplastic Anemia

- The report reviews pipeline therapeutics for Aplastic Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Aplastic Anemia therapeutics and enlists all their major and minor projects

- The report assesses Aplastic Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Aplastic Anemia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Aplastic Anemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Aplastic Anemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Request Sample Copy of This Report @ http://www.radiantinsights.com/research/aplastic-anemia-pipeline-review-h1-2016/request-sample          

Anaplastic Oligoastrocytoma Market Share, Size, Symptoms, Treatment, Causes, Overview and Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Anaplastic Oligoastrocytoma - Pipeline Review, H1 2016', provides an overview of the Anaplastic Oligoastrocytoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Oligoastrocytoma

- The report reviews pipeline therapeutics for Anaplastic Oligoastrocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Anaplastic Oligoastrocytoma therapeutics and enlists all their major and minor projects

- The report assesses Anaplastic Oligoastrocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Anaplastic Oligoastrocytoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Anaplastic Oligoastrocytoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Anaplastic Oligoastrocytoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Request Sample Copy of This Report @ http://www.radiantinsights.com/research/anaplastic-oligoastrocytoma-pipeline-review-h1-2016/request-sample         

Global & Usa Cancer Immunotherapy Market Growth, Trends, Analysis, Outlook and Overview 2020 by Radiant Insights

This report provides a comprehensive overview of the size of cancer immunotherapy market, the segmentation of the market, key players and the vast potential of therapies that are in clinical trials. Oncologic therapeutics cannot cure cancer and yet in 2014, the overall market for cancer therapeutics stood at about $84.3 billion.  Any drug that can provide a reasonable survival of more than five years for cancer patients can achieve a blockbuster status. Within cancer therapeutics, immunotherapeutic drugs have gained worldwide acceptance, because they are targeted drugs targeting only cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone. This report describes the evolution of such a huge market in 20 chapters supported by over 180 tables and figures in 317 pages.

Get Full Details On: http://www.radiantinsights.com/research/global-usa-cancer-immunotherapy-market-analysis-to-2020

• An overview of cancer immunotherapy that includes: monoclonal antibodies, cancer vaccines and non-specific cancer immunotherapies and CAR T therapies.

• Focus on current trends in cancer immunotherapies that include: anti-PD-1 drugs, Dendritic cell vaccines, T-cell therapies and cancer vaccines.

• Insight into the challenges faced by drug developers, particularly about the success vs. failure ratios in developing cancer immunotherapy drugs.

• Descriptions of more than 23 cancer immunotherapeutics approved and used as targeted drugs

• Insight into the various immunotherapeutics available for specific cancer types.

• Description and data for the prevalence of cancer types that are addressed by cancer immunotherapeutics.

• Overall global cancer therapeutics market, leading market players and the best selling cancer drugs.

• Detailed account of the market for cancer immunotherapeutics by geography, indication, company and individual drugs.

• Profiles, marketed products and products in the pipeline of 79 companies that are mostly located in the U.S. and Europe.

• Summary table to identify the category of immunotherapy drug offered by the 79 companies.

The report is supported by over 180 tables & figures over 317 pages. This report is presented as follows:

The global market for cancer immunotherapy by the following sub-categories are presented:

-By Segment (Monoclonal Antibodies, Cancer Vaccines, Non-Specific Therapies, Checkpoint Inhibitors)

-By Product Segment (Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Adopted Cell Therapy (ACT) & IDO Inhibitors)

-By Company (e.g Amgen, Merck, Eli Lilly, GlaxoSmithKline, Janssen, Genentech, Roche, Bristol Myers Squibb)

About Us:

Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Contact Details:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

28 2nd Street,

Suite 3036 San Francisco,

CA 94105 United States

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Website: http://www.radiantinsights.com/

Email: sales@radiantinsights.com

Visit our Blog: http://chemicalsandmaterialsri.blogspot.com

Chinese Medical Device GMP Regulations Market Share, Size, Analysis, Key Trends and Opportunities 2016: Radiant Insights

Summary

China is one of the fastest growing global economies with a fifth population in the world, and is one of the largest healthcare markets around the world. Along with sustained economic and population growth as well as an ageing population, Chinese healthcare market has maintained annually average growth rate above 16 % since 1990s. Among them, medical devices represented dynamical growth since 2000s. By 2014, total value of medical devices on Chinese healthcare market has reached 255.6 billion RMB (about 40.25 billion US dollars). Medical devices have been widely used in the process of disease prevention, diagnosis, therapy, care and rehabilitation. On the Chinese medical device market, imported overseas medical devices made by overseas and multinational medical device manufacturers account for about a half, in which the high-tech and high-valued medical devices, such as magnetic resonance imaging (MRI) equipments, computed tomography (CT) equipments are almost monopolized by GE, Siemens, Philips and other overseas and multinational companies. It is estimated that Chinese medical device market will be likely to be more than 340 billion RMB (about 53.15 billion US dollars) by 2015, and will surpass Japan to become the second largest medical device market behind the United States. Undoubtedly, China has an indispensable medical device market for overseas and multinational medical device companies. It’s definitely a field worth playing on.

Get Full Details On: http://www.radiantinsights.com/research/latest-guide-to-chinese-medical-device-gmp-regulations

However, since October 2014, Chinese regulatory authorities have significantly changed the regulations on medical devices. China Food and Drug Administration (CFDA) issued the latest Chinese Good Manufacturing Practice (GMP) Regulations for Medical Devices on December 29, 2014, which has come into force as March 1, 2015. On July 10, 2015, China Food and Drug Administration (CFDA) further issued the latest Implementation Regulations of Good Manufacturing Practice (GMP) for Sterile Medical Devices, Implementation Regulations of Good Manufacturing Practice (GMP) for Implantable Medical Devices as the appendices of the latest Chinese Good Manufacturing Practice (GMP) Regulations for Medical Devices respectively. They have come into force as October 1, 2015. Furthermore, on September 25, 2015, China Food and Drug Administration (CFDA) issued the latest On-site Inspection Guideline of Good Manufacturing Practice (GMP) for Medical Devices, On-site Inspection Guideline for Sterile Medical Device GMP Implementation Regulations, and On-site Inspection Guideline for Implantable Medical Device GMP Implementation Regulations. Everything changed.

Global Blood Processing Devices and Consumables Market is Expected to Grow at a CAGR of 8.52% by 2020

About Blood Processing Devices and Consumables

Globally, blood processing devices and consumables are getting attention from various healthcare institutions and other medical facilities where blood storage and transfusion have been part of improved patient treatment. Cord blood processing is gaining critical importance for stem cell research as well as blood disease therapy and the limited availability of cord blood is an urgent market need. Electrically aided centrifugal technique and novel filter using gentle gravity-dependent flow techniques are gaining prominence for cord blood processing.

Technavio's analysts forecast the global blood processing devices and consumables market to grow at a CAGR of 8.52% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global blood processing devices and consumables market for 2016-2020. To calculate the market size, we consider the revenue generated from the sales of blood processing devices and consumables.

The market is divided into the following segments based on geography:

- Americas

- APAC

- EMEA

Technavio's report, Global Blood Processing Devices and Consumables Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.